Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

238,824 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Pan J, et al. Among authors: zhang j, zhang y. J Clin Oncol. 2021 Oct 20;39(30):3340-3351. doi: 10.1200/JCO.21.00389. Epub 2021 Jul 29. J Clin Oncol. 2021. PMID: 34324392 Clinical Trial.
A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia.
Hu Y, Wang J, Wei G, Yu J, Luo Y, Shi J, Wu W, Zhao K, Xiao L, Zhang Y, Wu Z, Xu H, Chang AH, Huang H. Hu Y, et al. Among authors: zhang y. Bone Marrow Transplant. 2019 Aug;54(8):1208-1217. doi: 10.1038/s41409-018-0403-2. Epub 2018 Dec 5. Bone Marrow Transplant. 2019. PMID: 30518980
Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.
Wang J, Hu Y, Yang S, Wei G, Zhao X, Wu W, Zhang Y, Zhang Y, Chen D, Wu Z, Xiao L, Chang AH, Huang H, Zhao K. Wang J, et al. Among authors: zhang y. Biol Blood Marrow Transplant. 2019 Jun;25(6):1092-1098. doi: 10.1016/j.bbmt.2019.02.008. Epub 2019 Feb 12. Biol Blood Marrow Transplant. 2019. PMID: 30769193 Free article.
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
Pan J, Niu Q, Deng B, Liu S, Wu T, Gao Z, Liu Z, Zhang Y, Qu X, Zhang Y, Liu S, Ling Z, Lin Y, Zhao Y, Song Y, Tan X, Zhang Y, Li Z, Yin Z, Chen B, Yu X, Yan J, Zheng Q, Zhou X, Gao J, Chang AH, Feng X, Tong C. Pan J, et al. Among authors: zhang y. Leukemia. 2019 Dec;33(12):2854-2866. doi: 10.1038/s41375-019-0488-7. Epub 2019 May 20. Leukemia. 2019. PMID: 31110217 Clinical Trial.
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.
Wang Y, Yang Y, Hong R, Zhao H, Wei G, Wu W, Xu H, Cui J, Zhang Y, Chang AH, Hu Y, Huang H. Wang Y, et al. Among authors: zhang y. Blood Cancer J. 2020 Oct 19;10(10):105. doi: 10.1038/s41408-020-00371-6. Blood Cancer J. 2020. PMID: 33077713 Free PMC article. Clinical Trial. No abstract available.
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia.
Li X, Guo X, Zhu Y, Wei G, Zhang Y, Li X, Xu H, Cui J, Wu W, He J, Ritchie ME, Weiskittel TM, Li H, Yu H, Ding L, Shao M, Luo Q, Xu X, Teng X, Chang AH, Zhang J, Huang H, Hu Y. Li X, et al. Among authors: zhang j, zhang y. Mol Ther. 2021 Feb 3;29(2):645-657. doi: 10.1016/j.ymthe.2020.11.028. Epub 2020 Dec 3. Mol Ther. 2021. PMID: 33278564 Free PMC article.
CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin's Lymphoma.
Xue Y, Lai X, Li R, Ge C, Zeng B, Li Z, Fu Q, Zhao L, Dong S, Yang J, Guo J, Meng Q, Tan Q, Li Z, Ding H, Zhang Y, Liu S, Chang AH, Yao H, Luo R. Xue Y, et al. Among authors: zhang y. Front Oncol. 2021 Feb 2;10:607362. doi: 10.3389/fonc.2020.607362. eCollection 2020. Front Oncol. 2021. PMID: 33604290 Free PMC article.
Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy.
Zhang M, Zhou L, Zhao H, Zhang Y, Wei G, Hong R, Wu W, Xu H, Wang L, Ni F, Cui J, Peng S, Huang CH, Chang AH, Hu Y, Huang H. Zhang M, et al. Among authors: zhang y. Clin Cancer Res. 2021 Dec 1;27(23):6384-6392. doi: 10.1158/1078-0432.CCR-21-2031. Epub 2021 Sep 21. Clin Cancer Res. 2021. PMID: 34548316 Free PMC article.
238,824 results
You have reached the last available page of results. Please see the User Guide for more information.